spacer
home > ict > winter 2021 > automating regulatory data to drive digital transformation
PUBLICATIONS
International Clinical Trials

Automating Regulatory Data to Drive Digital Transformation


Data quality is at the heart of digital transformation. Yet, many life science companies are still failing to get up to date and find consistent data to talk to each other across integrated systems. The goal is not only to automate and integrate internal processes, but also to automate the sharing of that data with regulatory authorities, with the aim of speeding up the time it takes to get new or improved drugs to patients. Technology can help, but there are steps that pharmaceutical companies should begin to take now to improve interoperability.

Data are at the heart of regulatory processes in the pharma sector. Regulatory systems contain data on products and their licences. There is also procedural data, recording interactions with the authorities about a licence, from the initial application through to post-authorisation changes to the licence. Elsewhere, expert functions, from manufacturing to clinical teams, generate the basic data that feed the regulatory dossier supporting the licence. Typically, there is no direct communication between regulatory systems and expert functions systems. Manufacturing or clinical teams collate their data into a summary document and send them to the regulatory function. The regulatory team then takes those data and pulls them together in a submission dossier, ready to send to competent authorities for approval.

In manufacturing and the supply chain, the enterprise resource planning system typically holds data about products and materials. Meanwhile, in the regulatory function, there will be a regulatory information management system, which also contains data about the same products, but from the perspective of regulatory approval. Those systems are most often in completely separate worlds, with little or no interoperability. Yet, a change made in the manufacturing world must be reflected in the licence. Similar issues apply between the systems for management of clinical trials and the regulatory tracking of clinical trials applications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Duncan van Rijsbergen is Associate Director Regulatory Affairs at Iperion, a globally-operating life science consultancy firm, which is paving the way to digital healthcare by supporting standardisation and ensuring the right technology, systems, and processes are in place to enable insightful business decision-making and innovation.

duncan.vanrijsbergen@iperion.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Volga-Dnepr Group Strengthens its Global Healthcare Team

Volga-Dnepr Group, the group of international air cargo carriers with 30+ years of profound expertise in transporting various types of cargo, has strengthened its Global Healthcare Team to support its customers worldwide with comprehensive logistics solutions for their pharmaceutical products. The team will be led by Yulia Celetaria, Healthcare Director who will be in charge of smooth operations of the Group, alignment of dedicated healthcare and life-saving services with the usage of the Groupís unique freighter fleet, network connections through scheduled flights and charter options. While previously working for AirBridgeCargo Airlines, where she started her professional journey back in 2005, Yulia has been able to upscale her knowledge, expertise and gain the right experience necessary to meet the 2020 logistics challenge of the whole pharmaceutical industry.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As todayís global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement